| |
LC+normal(n=70) |
LC+emphysema(n=26) |
LC+fibrosis(n=10) |
LC+CPFE(n=17) |
| Age, years old |
72.5±1.5 |
78.8±2.0 |
73.8±2.1 |
73.9±1.9 |
| Gender, female/male |
31/39 |
3/23* |
1/9 |
1/16* |
| Route of diagnosis, n(%) |
| Screening, incidental |
46 (65.7%) |
15 (57.7%) |
4 (40.0%) |
10 (58.8%) |
| Symptoms |
24 (34.3%) |
11 (42.3%) |
6 (60.0%) |
7 (41.2%) |
| Histology of lung cancer, n(%) |
| Small cell carcinoma |
5 (7.1%) |
3 (11.5%) |
2 (20.0%) |
1 (5.9%) |
| Squamous cell carcinoma |
11 (15.7%) |
10 (38.5%) |
4 (40.0%) |
10 (58.8%) ** |
| Adenocarcinoma |
50 (71.4%) |
11 (42.3%) |
4 (40.0%) |
5 (29.4%) * |
| Large cell carcinoma |
3 (4.3%) |
2 (7.7%) |
0 (0.0%) |
0 (0.0%) |
| Other non-small cell carcinoma |
1 (1.4%) |
0 (0.0%) |
0 (0.0%) |
1 (5.9%) |
| Clinical stage of non-small cell lung cancer, n(%) |
| StageⅠA,B |
31 (47.7%) |
5 (21.7%) |
1 (12.5%) |
6 (37.5%) |
| StageⅡA,B |
5 (7.7%) |
5 (21.7%) |
1 (12.5%) |
5 (31.3%) |
| StageⅢA,B |
7 (10.8%) |
3 (13.0%) |
1 (12.5%) |
3 (18.8%) |
| StageⅣ |
22 (33.8%) |
10 (43.5%) |
5 (62.5%) |
2 (12.5%) |
| Advanced stage(ⅢB,Ⅳ) |
27 (41.5%) |
11 (47.8%) |
5 (62.5%) |
5 (31.3%) |
| Clinical stage of small cell lung cancer, n(%) |
| Limited disease |
3 (60.0%) |
2 (66.7%) |
1 (50.0%) |
1 (100.0%) |
| Extended disease |
2 (40.0%) |
1 (33.3%) |
1 (50.0%) |
0 (0.0%) |
| Initial treatment for lung cancer, n(%) |
| Surgery |
40 (57.1%) |
8 (30.8%) |
3 (30.0%) |
8 (47.1%) |
| Chemotherapy |
15 (21.4%) |
7 (26.9%) |
2 (20.0%) |
7 (41.2%) |
| Radiation |
4 (5.7%) |
1 (3.8%) |
0 (0.0%) |
0 (0.0%) |
| Best supportive care |
14 (20.0%) |
10 (38.5%) |
5 (50.0%) |
2 (11.8%) |
| Primary site of lung cancer, n(%) |
| Right upper lobe |
21 (30.0%) |
5 (19.2%) |
3 (30.0%) |
3 (17.6%) |
| Right middle lobe |
3 (4.3%) |
1 (3.8%) |
2 (20.0%) |
0 (0.0%) |
| Right lower lobe |
25 (35.7%) |
12 (46.2%) |
0 (0.0%) |
6 (35.3%) |
| Right hilum |
1 (1.4%) |
2 (7.7%) |
0 (0.0%) |
0 (0.0%) |
| Left upper lobe |
9 (12.9%) |
3 (11.5%) |
3 (30.0%) |
4 (23.5%) |
| Left lower lobe |
10 (14.3%) |
3 (11.5%) |
2 (20.0%) |
4 (23.5%) |
| Left hilum |
1 (1.4%) |
0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
| Location of primary mass, n(%) |
| Upper lobe |
30 |
8 |
6 |
7 |
| Non-subpleural |
21 (70.0%) |
4 (50.0%) |
2 (33.3%) |
5 (71.4%)† |
| Subpleural |
9 (30.0%) |
3 (37.5%) |
3 (50.0%) |
2 (28.8%)‡ |
| Not-differentiated |
0 (0.0%) |
1 (12.5%) |
1 (16.7%) |
0 (0.0%) |
| Other sites |
40 |
18 |
4 |
10 |
| Non-subpleural |
20 (50.0%) |
7 (38.9%) |
2 (50.0%) |
2 (20.0%) |
| Subpleural |
16 (40.0%) |
10 (55.6%) |
2 (50.0%) |
8 (80.0%) |
| Not-differentiated |
4 (10.0%) |
1 (5.6%) |
0 (0.0%) |
0 (0.0%) |
| Non-emphysematous area |
N/A |
2 (7.7%) |
N/A |
4 (23.5%) |
| Emphysematous area |
N/A |
24 (92.3%) |
N/A |
13 (76.5%) |
| Non-fibrotic area |
N/A |
N/A |
3 (30.0%) |
4 (23.5%) |
| Fibrotic area |
N/A |
N/A |
7 (70.0%) |
13 (76.5%) |
| In-fibrotic area |
N/A |
N/A |
0 (0.0%) |
4 (30.8%) |
| Fibrotic junction area |
N/A |
N/A |
7 (100.0%) |
9 (69.2%) |
|
